The two Chrysanthemum cinerariaefolium extracts opposite are currently making their way through the review programme under the Biocidal Products Regulation (EU) No 528/2012. The EU Biocidal Product Committee completed its review in September 2021...

Companies need to understand that biostimulants are still an evolving regulatory area in the US. This means claims that are allowed in other countries may prove to be problematic for companies looking to register a product in the states...

In this insight piece we look at how to lay the groundwork for a smoother authorisation experience in the European Union (EU) and Great Britain (GB) under their separate BPR regimes. The regulatory landscape for biocidal products has changed...